SCHEMBL5136148

SCHEMBL5136148

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(CCCC)Cc1cccc(O)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 8/20 0.40
OPRM1 P35372 7/20 0.40
OPRD1 P41143 7/20 0.40
DRD2 P14416 6/20 0.40
DRD3 P35462 6/20 0.40
TSHR P16473 1/20 0.38
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
C5AR1 P21730 1/20 0.35
HSD17B1 P14061 1/20 0.33
HSD17B2 P37059 1/20 0.33
DRD1 P21728 2/20 0.32
DRD4 P21917 2/20 0.32
DRD5 P21918 2/20 0.32
HTR1A P08908 1/20 0.32
BCHE P06276 1/20 0.32
TLR7 Q9NYK1 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134818 0.94 TSHR (0.39) OPRK1OPRM1OPRD1DRD2DRD3
SCHEMBL5135184 0.91 TSHR (0.38) TSHRNR1H3C5AR1TLR7PDE4B
SCHEMBL5136624 0.90 TSHR (0.40) TSHRNR1H3C5AR1BCHEPDE4B
SCHEMBL5135939 0.87 HSP90AA1 (0.38) TSHRNR1H2NR1H3TLR7
SCHEMBL5136862 0.86 C5AR1 (0.36) TSHRC5AR1
SCHEMBL5134566 0.85 TSHR (0.41) OPRK1OPRD1TSHRNR1H3C5AR1
SCHEMBL5135309 0.85 TLR7 (0.41) TLR7
SCHEMBL5137324 0.85 ACHE (0.36) TSHRC5AR1BCHETLR7
SCHEMBL5137355 0.85 TSHR (0.39) TSHRNR1H3C5AR1TLR7PDE4B
SCHEMBL5073855 0.85 TSHR (0.36) TSHRC5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed